

Edgar Filing: SANOFI SYNTHELABO SA - Form 6-K

SANOFI SYNTHELABO SA
Form 6-K
August 19, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2004

Commission File Number: 001-31368

SANOFI-SYNTHELABO
(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____

This Report on Form 6-K shall be deemed to be incorporated by reference into Sanofi-Synthelabo's Registration Statement on Form F-4 (Registration No. 333-112314), as post-effectively amended and declared effective on May 13, 2004 by the United States Securities Exchange Commission, and the related prospectus, dated April 9, 2004, and the prospectus supplement, dated May 27, 2004, each filed pursuant to Rule 424(b) under the United States Securities Act of 1933, as amended, and shall be part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

[SANOFI-SYNTHELABO LOGO]

[GRAPHIC] Investor Relations

Edgar Filing: SANOFI SYNTHELABO SA - Form 6-K

Paris, August 19th, 2004

Dear Madam, Dear Sir,

A CONFERENCE CALL for financial analysts, institutional investors and journalists will be organized on TUESDAY, AUGUST 31ST, 2004 AT 3.00 P.M. (Paris time) to present 2004 HALF-YEAR RESULTS, and INTERIM CLINICAL DATA (RIO-EUROPE ONE-YEAR DATA) OF ACOMPLIA (TM) IN OBESITY. This conference will be held in English.

In order to participate in the conference call, the following numbers are to be dialed 10 minutes before it starts :

FRANCE :	00 33 (0) 1 70 70 60 60	CODE : 902488
UNITED KINGDOM :	44 (0) 20 7784 10 04	CODE : 902488
USA :	1 718 354 11 52	CODE : 902488

The slides will be available on our website (www.sanofi-synthelabo.com) on Tuesday, August 31st from 10:00 a.m.

This conference will be broadcast live on our website

No recorded version will be archived for this conference.

Yours sincerely,

Philippe Goupit

INVESTOR RELATIONS DEPARTMENT

Philippe Goupit	Director of Investor Relations
Arnaud Delepine	Investor Relations Europe
Sanjay Gupta	Investor Relations US
Anne d'Halluin-Sulzer	Investor Relations
Loic Gonnet	Investor Relations

CONTACTS:

E-mail: investor-relations@sanofi-synthelabo.com	
Europe	US
Tel: + 33 1 53 77 45 45	Tel.: + 1 212 551 40 18
Fax: + 33 1 53 77 42 96	Fax: + 1 646 487 40 18

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Edgar Filing: SANOFI SYNTHELABO SA - Form 6-K

Dated: August 19, 2004

SANOFI-SYNTHELABO

By: /s/ Marie-Helene Laimay

Name: Marie-Helene Laimay
Title: Senior Vice President and
Chief Financial Officer